Hanna Irie, MD, PhD

Hanna Irie, MD, PhD is Associate Professor of Medicine in the Division of Hematology and Medical Oncology and in the Department of Oncological Sciences at the Icahn School of Medicine at Mount Sinai in New York City. She received her MD and PhD degrees from Harvard Medical School and completed a residency in Internal Medicine at Massachusetts General Hospital, followed by a clinical fellowship in Hematology and Medical Oncology at the Dana-Farber Cancer Institute. The focus of her research is to identify and validate novel therapeutic strategies for high risk and metastatic breast cancer. Recent research efforts have focused on oncogenes that regulate ephithelial-mesenchymal transition, drug resistance and metastases of breast cancer cells. Her laboratory collaborates with chemical biologists to develop and validate novel therapeutics targeting oncogenes and pathways. She and Dr. Port have worked on the generation of novel patient-derived estrogen receptor (ER)-positive and triple negative breast cancer (TNBC) models that enable validation of novel therapeutics. Their work further investigates biomarkers of chemotherapy and immunotherapy resistance to complement validation of these novel therapeutics. She and Dr. Port serve as co-PIs of the Mount Sinai Breast Tumor Biospecimen Repository which has banked over 500 breast tumor specimens.

“If not for BCRF, we would not have been able to take on the challenges associated with developing novel therapeutics for triple-negative breast cancer, from identification of new gene targets to drug design and validation.”